MediPoint: Total Hip Replacement - APAC Analysis and Market Forecasts

NEW YORK, Sept. 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Total Hip Replacement - APAC Analysis and Market Forecasts
http://www.reportlinker.com/p01623041/MediPoint-Total-Hip-Replacement---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

MediPoint: Total Hip Replacement - APAC Analysis and Market Forecasts

Summary

Osteoarthritis has become a global public health concern with no cure. It is the most common form of arthritis that is primarily due to wear and tear of the joints. With the aging global population, this is an indication that is growing rapidly with the hip being one of the most common joints afflicted. While the primary indication for total hip replacement (THR) is osteoporosis, the other major indications for THR are osteonecrosis and fractures to a lesser degree. As people live longer and with younger patients also receiving implants, the revision rates for primary hip replacements are also expected to rise. Primary hip replacement has become one of the most successful surgeries, with a variety of femoral and acetabular components available from a wide selection of manufacturers. This report focuses on the total primary hip replacement market along with primary revision market. The global hip replacement market has been estimated in this report which includes the Japan, China and India markets. The report provides unmet needs, future adoption and compounded annual growth rates (CAGR). GlobalData's analysis shows that the hip replacement market has become a mature market where products have become commodities. The future of the market lays on the ability of manufacturers to provide implants at a very low cost while continuing to provide the same level of clinical efficacy. The product development need lies primarily in revising the resurfacing products' articulating surface with new materials rather than developing new acetabular and femoral components. Additionally the major opportunity lies within the emerging markets which are the countries that have a higher CAGR and will provide the key for growth and grabbing market share.

Scope

- An overview of Osteoarthritis, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized APAC THR market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for THR
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the THR sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as Orthopedic Surgeon.

Reasons to buy

- Understand the trends shaping and driving the APAC THR Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the APAC THR market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in APAC THR market landscape? Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 16
1.2 List of Figures 26
2 Introduction 30
2.1 Catalyst 31
3 Disease Overview 32
3.1 Anatomy and Physiology 32
3.2 Pathophysiology 33
3.2.1 Overview 33
3.2.2 Osteoarthritis 34
3.2.3 Rheumatoid Arthritis 34
3.2.4 Post-traumatic Arthritis 35
3.2.5 Osteonecrosis 35
3.2.6 Injury 36
3.2.7 Bone Tumors 36
3.2.8 Other Diseases 36
3.3 Clinical Presentation 37
3.4 Clinical Outcomes 38
3.4.1 Overview 38
3.4.2 Conservative Therapy 40
3.4.3 Hip Arthroscopy 40
3.4.4 Hip Arthrodesis 41
3.4.5 Hemiarthroplasty (Partial) 42
3.4.6 Core Decompression 42
3.4.7 Hip Osteotomy 43
3.4.8 Resection Arthroplasty 43
3.4.9 Primary Total Hip Replacement 43
3.4.10 Revision Total Hip Replacement 45
3.4.11 Resurfacing Arthroplasty 46
3.4.12 Computer-Navigated Hip Replacement 47
3.5 Surgical Approaches 47
3.5.1 Anterolateral Approach 49
3.5.2 Posterior Approach 50
3.5.3 Direct Anterior Approach 50
3.5.4 Minimally Invasive Approaches 51
3.6 Epidemiology 51
3.6.1 APAC 53
3.7 Economic Impact 54
3.7.1 APAC 55
4 Competitive Assessment 56
4.1 Overview of Historical Designs 56
4.2 Marketed Products 57
4.2.1 Global Market Share 57
4.2.2 Primary Total Hip Replacement 58
4.2.3 Product Profiles by Company 59
5 Unmet Needs 196
5.1 Long-Term Clinical Data 196
5.2 Need for Continued Materials Research 196
5.3 Bearings 198
5.4 Refocus of Pipeline Products 199
5.5 Renewal of Resurfacing 200
5.6 Addressing the Learning Curve for Tier II Surgeons 201
5.7 Need for Cost Containment 203
5.8 Centralization 204
5.9 National Joint Registry 204
6 Pipeline Products 206
6.1 Overview 206
6.2 Primary Total Hip Pipeline Products 206
6.2.1 Exactech LPI Prime Hip System 206
6.2.2 EnduRo Bone-preserving Hip Stem 207
6.2.3 Deltamotion Acetabular Cup System 207
6.2.4 NovoSource Hip Implant 208
7 Industry Overview 209
7.1 Procedure Volumes 209
7.1.1 APAC 210
7.2 Market Access 211
7.2.1 APAC 211
7.3 Reimbursement Trends 212
7.3.1 Japan 213
7.3.2 China 214
7.3.3 India 215
7.4 Regulatory Issues/Recalls 216
7.4.1 DePuy Hip Replacement Recall 216
7.4.2 Stryker Hip Replacement Recall 217
7.4.3 Smith & Nephew Recall: R3 Metal Liners of the R3 Acetabular System 217
7.4.4 Zimmer Durom® Acetabular Component 217
7.4.5 Biomet Hip Replacement Complications 217
7.4.6 Wright Medical Conserve Hip Implant 218
7.4.7 The Corin Group Metal-on-Metal Hip Resurfacing 218
7.5 Mergers & Acquisitions / Key Partnerships 219
7.5.1 Medtronic Acquires China Kanghui Holdings 219
7.5.2 Tornier Acquires OrthoHelix Surgical Designs Inc. 219
7.5.3 DePuy Orthopaedics (Johnson & Johnson) and Synthes Inc. Merge 219
7.5.4 Italian Consortium 2IL Orthopaedics Ltd Acquires Corin Group 220
7.5.5 Zimmer Acquires Beijing Montagne Medical Device Co. Ltd. 220
7.5.6 Wright Medial Announces Agreement to Sell OrthoRecon Business to MicroPort Medical B.V. 220
8 Company Profiles 221
8.1 B. Braun 221
8.1.1 Overview 221
8.1.2 Portfolio Assessment 222
8.1.3 SWOT Analysis 222
8.2 Biomet Orthopedics 223
8.2.1 Overview 223
8.2.2 Portfolio Assessment 224
8.2.3 SWOT Analysis 227
8.3 Corentec Co. Ltd. 228
8.3.1 Overview 228
8.3.2 Portfolio Assessment 228
8.3.3 SWOT Analysis 229
8.4 Corin 229
8.4.1 Overview 229
8.4.2 Portfolio Assessment 230
8.4.3 SWOT Analysis 231
8.5 DePuy Synthes International 232
8.5.1 Overview 232
8.5.2 Portfolio Assessment 233
8.5.3 SWOT Analysis 236
8.6 Exactech 236
8.6.1 Overview 236
8.6.2 Portfolio Assessment 237
8.6.3 SWOT Analysis 239
8.7 Iconacy Orthopedic Implants LLC 239
8.7.1 Overview 239
8.7.2 Portfolio Assessment 240
8.7.3 SWOT Analysis 241
8.8 Implantcast GMBH 241
8.8.1 Overview 241
8.8.2 Portfolio Assessment 241
8.8.3 SWOT Analysis 243
8.9 JRI Orthopaedics 243
8.9.1 Overview 243
8.9.2 Portfolio Assessment 244
8.9.3 SWOT Analysis 245
8.10 Kyocera 245
8.10.1 Overview 245
8.10.2 Portfolio Assessment 246
8.10.3 SWOT Analysis 247
8.11 Limacorporate S.P.A 247
8.11.1 Overview 247
8.11.2 Portfolio Assessment 248
8.11.3 SWOT Analysis 249
8.12 Medacta 250
8.12.1 Overview 250
8.12.2 Portfolio Assessment 250
8.12.3 SWOT Analysis 251
8.13 Medtronic 252
8.13.1 Overview 252
8.13.2 Portfolio Assessment 253
8.13.3 SWOT Analysis 254
8.14 NovoSource Inc. 254
8.14.1 Overview 254
8.14.2 Portfolio Assessment 255
8.14.3 SWOT Analysis 256
8.15 Peter Brehm GMBH 256
8.15.1 Overview 256
8.15.2 Portfolio Assessment 257
8.15.3 SWOT Analysis 257
8.16 Serf Dedienne Santé 258
8.16.1 Overview 258
8.16.2 Portfolio Assessment 259
8.16.3 SWOT Analysis 260
8.17 Smith & Nephew 260
8.17.1 Overview 260
8.17.2 Portfolio Assessment 261
8.17.3 SWOT Analysis 263
8.18 Stelkast 263
8.18.1 Overview 263
8.18.2 Portfolio Assessment 264
8.18.3 SWOT Analysis 264
8.19 Stryker 265
8.19.1 Overview 265
8.19.2 Portfolio Assessment 266
8.19.3 SWOT Analysis 267
8.20 Tianjin Zhengtian Medical Instrument Co., Ltd. 268
8.20.1 Overview 268
8.20.2 Portfolio Assessment 268
8.20.3 SWOT Analysis 269
8.21 Tornier N.V. 270
8.21.1 Overview 270
8.21.2 Portfolio Assessment 271
8.21.3 SWOT Analysis 273
8.22 Wright Medical 273
8.22.1 Overview 273
8.22.2 Portfolio Assessment 274
8.22.3 SWOT Analysis 276
8.23 United Orthopedic Corporation 277
8.23.1 Overview 277
8.23.2 Portfolio Assessment 277
8.23.3 SWOT Analysis 278
8.24 Zimmer Holdings Inc. 279
8.24.1 Overview 279
8.24.2 Portfolio Assessment 280
8.24.3 SWOT Analysis 282
8.25 Other Companies 283
9 Market Drivers, Opportunities and Barriers 284
9.1 Market Drivers 284
9.1.1 Prevalence Rise 284
9.1.2 Expanding Indications 286
9.1.3 Availability and Lack of Long-Term Clinical Data 287
9.1.4 Fracture Incidence 287
9.1.5 Patient Demand and Awareness 287
9.2 Opportunities 288
9.2.1 Revision Surgery 288
9.2.2 Emerging Markets 288
9.2.3 Continued Materials Research 289
9.2.4 Corporate Promotions and Teaching Seminars 290
9.2.5 Advancement towards Cost Reduction 290
9.3 Market Barriers 291
9.3.1 Market Barriers 291
10 Country Outlooks & Forecasts 295
10.1 APAC Markets Overview 295
10.2 Japan Market Analysis 297
10.3 China Market Analysis 299
10.4 India Market Analysis 300
11 Appendix 303
11.1 Abbreviations 303
11.2 Bibliography 305
11.3 Report Methodology 322
11.3.1 Overview 322
11.3.2 Coverage 322
11.3.3 Secondary Research 323
11.3.4 Forecasting Methodology 323
11.3.5 Primary Research – Key Opinion Leader Interviews 325
11.3.6 Expert Panel Validation 325
11.4 Physicians and Specialists Included in this Study 326
11.4.1 Dr. Alessandro Aprato 326
11.4.2 Dr. Fran Channa 326
11.4.3 Joseph Daniel FRCS MS (Orth) 326
11.4.4 Dr. Alejandro Gonzalez Della Valle 326
11.4.5 Dr. Moussa Hamadouche 326
11.4.6 Dr. Sheng-Li Huang and Xi-Jing He 326
11.4.7 Dr. Ayumi Kaneuji 327
11.4.8 Dr. Yuichi Mitani 327
11.4.9 Dr. Ning Lu 327
11.4.10 Dr. Deepak Saini 327
11.4.11 Dr. Lafayette Lage 327
11.4.12 Dr. Christoph Zilkens 327
11.5 About the Authors 328
11.5.1 Analysts 328
11.5.2 Global Head of Healthcare 329
11.6 About MediPoint 330
11.7 About GlobalData 330
11.8 Disclaimer 330
1.1 List of Tables

Table 1: Clinical Symptoms and Descriptions 37
Table 2: Advantages and Disadvantages of Hip Resurfacing 47
Table 3: Surgical Approaches Comparison 48
Table 4: Global Prevalence of Osteoarthritis in the Major APAC Markets, 2010–2019 52
Table 5: Direct and Indirect Costs of Arthritis 54
Table 6: APAC Product Costs 55
Table 7: Bicontact Universal Hip System (B. Braun) 60
Table 8: Clinical Studies Bicontact Universal Hip System (B. Braun) 61
Table 9: SWOT Bicontact Universal Hip System 61
Table 10: Excia Hip Stem (B. Braun) 63
Table 11: Clinical Studies Excia Hip Stem (B. Braun) 64
Table 12: SWOT Excia Hip Stem 64
Table 13: Metha® Short Hip Stem (B. Braun) 66
Table 14: Clinical Studies Metha® Short Hip Stem (B. Braun) 67
Table 15: SWOT Metha® Short Hip Stem 67
Table 16: TRJ Cementless Hip Endoprosthesis System (B. Braun) 69
Table 17: SWOT TRJ Cementless Hip Endoprosthesis System 70
Table 18: Plasmacup SC Acetabular Cup (B. Braun) 71
Table 19: Balance Femoral Component (Biomet) 72
Table 20: Clinical Studies Balance Femoral Component (Biomet) 73
Table 21: SWOT Balance Femoral Component 73
Table 22: Bi-Metric Femoral Components (Biomet) 74
Table 23: Clinical Studies Bi-Metric Femoral Components (Biomet) 75
Table 24: SWOT Bi-Metric Femoral Components 75
Table 25: Bio-Moore II Hip System (Biomet) 76
Table 26: Clinical Studies Bio-Moore II Hip System (Biomet) 77
Table 27: SWOT Bio-Moore II Hip System 77
Table 28: Generation 4 Polished Hip System (Biomet) 78
Table 29: SWOT Generation 4 Polished Hip System 79
Table 30: Integral Porous Primary Hip System (Biomet) 80
Table 31: Clinical Studies Integral Porous Hip System (Biomet) 80
Table 32: SWOT Integral Porous Hip System Femoral Components 81
Table 33: Mallory Femoral Component (Biomet) 82
Table 34: Clinical Studies Mallory Femoral Component (Biomet) 82
Table 35: SWOT Mallory Femoral Component 83
Table 36: Progressive Total Hip System (Biomet) 84
Table 37: SWOT Progressive Total Hip System 84
Table 38: Rx 90 Smooth Primary Femoral Component (Biomet) 85
Table 39: SWOT Rx 90 Smooth Primary Femoral Component 86
Table 40: Stanmore Hip System (Biomet) 87
Table 41: Clinical Studies Stanmore Hip System (Biomet) 87
Table 42: SWOT Stanmore Hip System 88
Table 43: Taperloc and Balance Microplasty Hip Stems (Biomet) 89
Table 44: Clinical Studies Taperloc and Balance Microplasty Hip Stems (Biomet) 89
Table 45: SWOT Taperloc and Balance Microplasty Hip Stems 90
Table 46: Acetabular Systems (Biomet) 90
Table 47: Bencox Stems (Corentec Co. Ltd) 92
Table 48: Clinical Studies Bencox Stems (Corentec Co. Ltd) 92
Table 49: SWOT Bencox Stems 93
Table 50: Bencox Acetabular Systems (Corentec Co. Ltd.) 94
Table 51: MetaFix (Corin) 95
Table 52: SWOT MetaFix 95
Table 53: MiniHip (Corin) 97
Table 54: SWOT MiniHip 97
Table 55: MRP-Titan (Corin) 99
Table 56: SWOT MRP-Titan 99
Table 57: TaperFit (Corin) 101
Table 58: SWOT TaperFit 101
Table 59: Trinity Acetabular System (Corin) 103
Table 60: Cenator Acetabular Cup (Corin) 104
Table 61: Cementless Systems (DePuy Synthes) 106
Table 62: Clinical Studies Cementless Systems (DePuy Synthes) 106
Table 63: SWOT DePuy Synthes Cementless Systems 107
Table 64: Cemented Systems (DePuy Synthes) 108
Table 65: Clinical Studies Cemented Systems (DePuy Synthes) 108
Table 66: SWOT DePuy Synthes Cemented Systems 108
Table 67: DePuy Synthes Acetabular Systems (DePuy Synthes) 110
Table 68: AcuMatch Femoral Stems (Exactech) 111
Table 69: Clinical Studies AcuMatch Femoral Stems (Exactech) 112
Table 70: SWOT AcuMatch Femoral Stems 112
Table 71: Novation Femoral Stems (Exactech) 114
Table 72: Clinical Studies Novation Femoral Stems (Exactech) 114
Table 73: SWOT Novation Femoral Stems 115
Table 74: Exactech Acetabular Systems (Exactech) 115
Table 75: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 117
Table 76: SWOT i-Hip Total Hip Implant 117
Table 77: EcoFit Femoral Stem (Implantcast GMBH) 119
Table 78: Aida Short Femoral Stem (Implantcast GMBH) 120
Table 79: AJS Hip System (Implantcast GMBH) 121
Table 80: DiaLoc Hip Stem (Implantcast GMBH) 122
Table 81: LOAD SHIFT Hip Stem (Implantcast GMBH) 123
Table 82: Ceraco Hip Stem (Implantcast GMBH) 124
Table 83: IC Straight Stem Type I and Type II (Implantcast GMBH) 125
Table 84: Bicana Hip Stem (Implantcast GMBH) 126
Table 85: SWOT Implantcast GMBH Femoral Stems 126
Table 86: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 128
Table 87: Aeon Hip System (JRI Orthopaedics) 129
Table 88: SWOT Aeon Hip System 129
Table 89: Furlong Hip System and Evolution System (JRI Orthopaedics) 130
Table 90: Clinical Studies Furlong Hip System (JRI Orthopaedics) 131
Table 91: SWOT Furlong Hip System and Evolution System 131
Table 92: Limacorporate Cementless Femoral Stems (Limacorporate SPA) 133
Table 93: SWOT Limacorporate Cementless Femoral Stems 133
Table 94: Cemented and Cementless Stems (Limacorporate SPA) 134
Table 95: SWOT Cemented and Cementless Stems (Limacorporate SPA) 135
Table 96: Limacorporate Acetabular Systems 135
Table 97: Cemented and Cementless Stems (Medacta) 137
Table 98: SWOT Medacta Stems 137
Table 99: Acetabular Cups and Femoral Heads (Medacta) 138
Table 100: Helicon Hip System (TGM Medical, wholly owned by Medtronic) 139
Table 101: SWOT Helicon Hip System 140
Table 102: Vektor Titan and Vektor CoCr (Peter Brehm GMBH) 141
Table 103: Clinical Studies Peter Brehm Stems (Peter Brehm GMBH) 142
Table 104: SWOT Peter Brehm Products 142
Table 105: Libra and Sagittal EVL (Serf Dedienne Santé) 144
Table 106: SWOT Libra and Sagittal EVL 144
Table 107: Acetabular Cups (Serf Dedienne Santé) 146
Table 108: Echelon and Synergy (Smith & Nephew) 148
Table 109: SWOT Echelon and Synergy 148
Table 110: Anthology Hip System (Smith & Nephew) 149
Table 111: SWOT Anthology Hip System 150
Table 112: CPCS and Spectron Hip System (Smith & Nephew) 151
Table 113: SWOT CPCS and Spectron Hip System 151
Table 114: Emperion and SMF Modular Stems (Smith & Nephew) 152
Table 115: SWOT Emperion and SMF Modular Stems 153
Table 116: Acetabular Cups (Smith & Nephew) 154
Table 117: ProClass Hip Stem (Stelkast) 155
Table 118: SWOT ProClass Hip Stem 155
Table 119: Progeny Hip Stem (Stelkast) 156
Table 120: SWOT Progeny Hip Stem 157
Table 121: Protract Hip Stem (Stelkast) 158
Table 122: SWOT Protract Hip Stem 158
Table 123: Provident Hip Stem (Stelkast) 159
Table 124: SWOT Provident Hip Stem 160
Table 125: Acetabular Cups (Stelkast) 162
Table 126: Cementless Stems (Stryker) 164
Table 127: SWOT Cementless Stems 164
Table 128: Cemented Stems (Stryker) 165
Table 129: SWOT Cemented Stems 166
Table 130: Acetabular Systems (Stryker) 167
Table 131: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 168
Table 132: SWOT Diamond Total Hip Implant 168
Table 133: Linea Stem (Tornier N.V.) 170
Table 134: SWOT Linea Stem 171
Table 135: Meije Duo Stem (Tornier N.V.) 172
Table 136: SWOT Meije Duo Stem 173
Table 137: Oceane Stem (Tornier N.V.) 174
Table 138: SWOT Oceane Stem 175
Table 139: Tornier Femoral Heads (Tornier N.V.) 176
Table 140: Oceane Cup (Tornier N.V.) 177
Table 141: Tornier Dynacup (Tornier N.V.) 178
Table 142: Tornier Dual Mobility (Tornier N.V.) 180
Table 143: Perfecta Cementless and Cemented Stems (Wright Medical) 181
Table 144: SWOT Perfecta Cementless and Cemented Stems 181
Table 145: Cementless Femoral Stems (Wright Medical) 183
Table 146: SWOT Cementless Femoral Stems 183
Table 147: Cemented Femoral Stems (Wright Medical) 184
Table 148: SWOT Cemented and Cementless Femoral Stems (Wright Medical) 185
Table 149: Acetabular Systems (Wright Medical) 186
Table 150: UTF and UTF Reduced Stem (United Orthopedic Company) 187
Table 151: SWOT UTF and UTF Reduced Stem 188
Table 152: Hip U1 and U2 Stems (United Orthopedic Corporation) 189
Table 153: SWOT Acetabular Systems (United Orthopedic Corporation) 189
Table 154: Acetabular Systems (United Orthopedic Corporation) 191
Table 155: Press-Fit Stems (Zimmer Holdings Inc.) 193
Table 156: SWOT Press-Fit Stems 193
Table 157: Acetabular Systems (Zimmer Holdings Inc.) 195
Table 158: Exactech LPI Prime Hip System (Exactech) 207
Table 159: Company Profile – B. Braun 221
Table 160: B. Braun Product Portfolio 222
Table 161: SWOT Analysis – B. Braun 222
Table 162: Company Profile – Biomet Orthopedics 223
Table 163: Biomet Product Portfolio 225
Table 164: SWOT Analysis – Biomet Orthopedics 227
Table 165: Company Profile – Corentec Co. Ltd. 228
Table 166: Corentec Product Portfolio 228
Table 167: SWOT Analysis – Corentec Co. Ltd. 229
Table 168: Company Profile – Corin Group 230
Table 169: Corin Group Product Portfolio 231
Table 170: SWOT Analysis – Corin Group 231
Table 171: Company Profile – DePuy Synthes International 233
Table 172: DePuy Synthes International Product Portfolio 234
Table 173: SWOT Analysis – DePuy Synthes International 236
Table 174: Company Profile – Exactech 237
Table 175: Exactech Product Portfolio 238
Table 176: SWOT Analysis – Exactech 239
Table 177: Company Profile – Iconacy Orthopedic Implants LLC 240
Table 178: Iconacy Orthopedic Implants LLC Product Portfolio 240
Table 179: SWOT Analysis – Iconacy Orthopedic Implants LLC 241
Table 180: Company Profile – Implantcast GMBH 241
Table 181: Implantcast GMBH Product Portfolio 242
Table 182: SWOT Analysis – Implantcast GMBH 243
Table 183: Company Profile – JRI Orthopaedics 243
Table 184: JRI Orthopaedics Product Portfolio 244
Table 185: SWOT Analysis – JRI Orthopaedics 245
Table 186: Company Profile – KYOCERA Medical Corporation 246
Table 187: KYOCERA Medical Corporation Product Portfolio 246
Table 188: SWOT Analysis – KYOCERA Medical Corporation 247
Table 189: Company Profile – Limacorporate S.P.A 248
Table 190: Limacorporate S.P.A Product Portfolio 248
Table 191: SWOT Analysis – Limacorporate S.P.A 249
Table 192: Company Profile – Medacta International 250
Table 193: Medacta International Product Portfolio 251
Table 194: SWOT Analysis – Medacta International 251
Table 195: Company Profile – Medtronic 252
Table 196: Medtronic Product Portfolio 253
Table 197: SWOT Analysis – Medtronic 254
Table 198: Company Profile – NovoSource Inc. 255
Table 199: NovoSource Inc. Product Portfolio 255
Table 200: SWOT Analysis – NovoSource Inc. 256
Table 201: Company Profile – Peter Brehm GMBH 256
Table 202: Peter Brehm GMBH Product Portfolio 257
Table 203: SWOT Analysis – Peter Brehm GMBH 257
Table 204: Company Profile – Serf Dedienne Santé 258
Table 205: Serf Dedienne Santé Product Portfolio 259
Table 206: SWOT Analysis – Serf Dedienne Santé 260
Table 207: Company Profile – Smith & Nephew 261
Table 208: Smith & Nephew Product Portfolio 262
Table 209: SWOT Analysis – Smith & Nephew 263
Table 210: Company Profile – Stelkast 263
Table 211: Stelkast Product Portfolio 264
Table 212: SWOT Analysis – Stelkast 264
Table 213: Company Profile – Stryker 266
Table 214: Stryker Product Portfolio 267
Table 215: SWOT Analysis – Stryker 267
Table 216: Company Profile – Tianjin Zhengtian Medical Instrument Co. Ltd. 268
Table 217: Tianjin Zhengtian Medical Instrument Co. Ltd. Product Portfolio 269
Table 218: SWOT Analysis – Tianjin Zhengtian Medical Instrument Co. Ltd. 269
Table 219: Company Profile – Tornier N.V. 271
Table 220: Tornier N.V. Product Portfolio 272
Table 221: SWOT Analysis – Tornier N.V. 273
Table 222: Company Profile – Wright Medical 274
Table 223: Wright Medical Product Portfolio 275
Table 224: SWOT Analysis – Wright Medical 276
Table 225: Company Profile – United Orthopedic Corporation 277
Table 226: United Orthopedic Corporation Product Portfolio 278
Table 227: SWOT Analysis – United Orthopedic Corporation 278
Table 228: Company Profile – Zimmer Holdings Inc. 280
Table 229: Zimmer Holdings Inc. Product Portfolio 281
Table 230: SWOT Analysis – Zimmer Holdings, Inc. 282
Table 231: Other Companies in the Global Hip Replacement Market 283
Table 232: Global Sales ($m) Forecast for THR, 2010–2019 295
Table 233: Japan Sales ($m) Forecast for THR, 2010–2019 297
Table 234: China Sales ($m) Forecast for THR, 2010–2019 299
Table 235: India Sales ($m) Forecast for THR, 2010–2019 301

1.2 List of Figures

Figure 1: Anatomy of the Hip 32
Figure 2: Treatment Paradigm for Hip Osteoarthritis 38
Figure 3: Treatment Paradigm for Hip Fractures 39
Figure 4: Hip Arthrodesis 41
Figure 5: Partial Hip Arthroplasty and Total Hip Arthroplasty 44
Figure 6: Surgical Approach Used by Orthopedic Surgeons Globally 48
Figure 7: Surgical Approach Used by Orthopedic Surgeons in North America 49
Figure 8: Population with Osteoarthritis in APAC, 2010–2019 54
Figure 9: Global Market Share for Reconstructive Products, 2012 57
Figure 10: Cementless, Cemented, Hybrid Product Usage by Orthopedic Surgeons, by Country 58
Figure 11: Bicontact Universal Hip System (B. Braun) 59
Figure 12: Excia Hip Stem (B. Braun) 62
Figure 13: Metha® Short Hip Stem (B. Braun) 65
Figure 14: TRJ Cementless Hip Endoprosthesis System (B. Braun) 68
Figure 15: Plasmacup SC Acetabular Cup (B. Braun) 70
Figure 16: Balance Femoral Component (Biomet) 72
Figure 17: Bi-Metric Femoral Components (Biomet) 74
Figure 18: Bio-Moore II Hip System (Biomet) 76
Figure 19: Generation 4 Polished Hip System (Biomet) 78
Figure 20: Integral Porous Primary Hip System (Biomet) 79
Figure 21: Mallory Femoral Component (Biomet) 81
Figure 22: Progressive Total Hip System (Biomet) 83
Figure 23: Rx 90 Smooth Primary Femoral Component (Biomet) 85
Figure 24: Stanmore Hip System (Biomet) 86
Figure 25: Taperloc and Balance Microplasty Hip Stems (Biomet) 88
Figure 26: Bencox Stems (Corentec Co. Ltd) 91
Figure 27: Bencox Acetabular Systems (Corentec Co. Ltd.) 93
Figure 28: MetaFix (Corin) 94
Figure 29: MiniHip (Corin) 96
Figure 30: MRP-Titan (Corin) 98
Figure 31: TaperFit (Corin) 100
Figure 32: Trinity Acetabular System (Corin) 102
Figure 33: Cenator Acetabular Cup (Corin) 104
Figure 34: Cementless Systems (DePuy Synthes) 105
Figure 35: Cemented Systems (DePuy Synthes) 107
Figure 36: DePuy Acetabular Systems (DePuy Synthes) 109
Figure 37: AcuMatch Femoral Stems (Exactech) 111
Figure 38: Novation Femoral Stems (Exactech) 113
Figure 39: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 116
Figure 40: EcoFit Femoral Stem (Implantcast GMBH) 118
Figure 41: Aida Short Femoral Stem (Implantcast GMBH) 119
Figure 42: AJS Hip System (Implantcast GMBH) 120
Figure 43: DiaLoc Hip Stem (Implantcast GMBH) 121
Figure 44: LOAD SHIFT Hip Stem (Implantcast GMBH) 122
Figure 45: Ceraco Hip Stem (Implantcast GMBH) 123
Figure 46: IC Straight Stem Type I and Type II (Implantcast GMBH) 124
Figure 47: Bicana Hip Stem (Implantcast GMBH) 125
Figure 48: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 127
Figure 49: Aeon Hip System (JRI Orthopaedics) 128
Figure 50: Furlong Hip System and Evolution System (JRI Orthopaedics) 130
Figure 51: Cemented and Cementless Stems (Limacorporate SPA) 134
Figure 52: Cemented and Cementless Stems (Medacta) 136
Figure 53: Helicon Hip System (TGM Medical wholly owned by Medtronic) 139
Figure 54: Vektor-Titan and Vektor-CoCr (Peter Brehm GMBH) 141
Figure 55: Libra and Sagitta EVL (Serf Dedienne Santé) 143
Figure 56: Acetabular Cups (Serf Dedienne Santé) 145
Figure 57: Echelon and Synergy (Smith & Nephew) 147
Figure 58: Anthology Hip System (Smith & Nephew) 149
Figure 59: CPCS and Spectron Hip System (Smith & Nephew) 150
Figure 60: Emperion and SMF Modular Stems (Smith & Nephew) 152
Figure 61: Acetabular Cups (Smith & Nephew) 153
Figure 62: ProClass Hip Stem (Stelkast) 154
Figure 63: Progeny Hip Stem (Stelkast) 156
Figure 64: Protract Hip Stem (Stelkast) 157
Figure 65: Provident Hip Stem (Stelkast) 159
Figure 66: Acetabular Systems (Stelkast) 161
Figure 67: Cementless Stems (Stryker) 163
Figure 68: Cemented Stems (Stryker) 165
Figure 69: Acetabular Systems (Stryker) 166
Figure 70: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 167
Figure 71: Linea Stem (Tornier N.V.) 169
Figure 72: Meije Duo Stem (Tornier N.V.) 171
Figure 73: Oceane Stem (Tornier N.V.) 173
Figure 74: Tornier Femoral Heads (Tornier N.V.) 175
Figure 75: Oceane Cup (Tornier N.V.) 176
Figure 76: Tornier Dynacup (Tornier N.V.) 178
Figure 77: Tornier Dual Mobility (Tornier N.V.) 179
Figure 78: Perfecta Cementless and Cemented Stems (Wright Medical) 180
Figure 79: Cementless Femoral Stems (Wright Medical) 182
Figure 80: Profemur Gladiator (Wright Medical) 184
Figure 81: Acetabular Systems (Wright Medical) 185
Figure 82: UTF and UTF Reduced Stem (United Orthopedic Corporation) 187
Figure 83: Hip U1 and U2 Stems (United Orthopedic Corporation) 188
Figure 84: Acetabular Systems (United Orthopedic Corporation) 190
Figure 85: Press-Fit Stems (Zimmer Holdings Inc.) 192
Figure 86: Acetabular Systems (Zimmer Holdings Inc.) 194
Figure 87: Asia-Pacific Primary Hip Arthroplasty Procedure Volumes (2010–2019) 210
Figure 88: Global Sales ($m) Forecast for THR and Revision, 2010–2019 296
Figure 89: Japan Sales ($m) Forecast for THR, 2010–2019 298
Figure 90: China Sales ($m) Forecast for THR, 2010–2019 300
Figure 91: India Sales ($m) Forecast for THR, 2010–2019 302

Companies Mentioned

B. Braun
Biomet Orthopedics
Corentec Co. Ltd.
Corin
DePuy Synthes International
Exactech
Iconacy Orthopedic Implants LLC
Implantcast GMBH
JRI Orthopaedics
Kyocera
Limacorporate S.P.A
Medacta
Medtronic
NovoSource Inc.
Peter Brehm GMBH
Serf De


To order this report: MediPoint: Total Hip Replacement - APAC Analysis and Market Forecasts
http://www.reportlinker.com/p01623041/MediPoint-Total-Hip-Replacement---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker